Neurogene Inc (NGNE) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Neurogene Inc (NGNE) has a cash flow conversion efficiency ratio of -0.110x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-26.12 Million) by net assets ($237.78 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Neurogene Inc (NGNE) total market value for the company's overall valuation and market capitalisation.
Neurogene Inc - Cash Flow Conversion Efficiency Trend (2011–2025)
This chart illustrates how Neurogene Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Neurogene Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Neurogene Inc ranked by their cash flow conversion efficiency. Explore Neurogene Inc (NGNE) cash flow quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
eXp World Holdings, Inc.
NASDAQ:AGNT
|
0.138x |
|
Drugs Made In America Acquisition II Corp. Ordinary Shares
NASDAQ:DMII
|
0.000x |
|
Iperionx Ltd
AU:IPX
|
0.000x |
|
International Tower Hill Mines Ltd
TO:ITH
|
0.010x |
|
Pubmatic Inc
NASDAQ:PUBM
|
0.085x |
|
Skjern Bank A/S
CO:SKJE
|
0.007x |
|
Ciputra Development Tbk
JK:CTRA
|
0.004x |
|
Grendene S.A
SA:GRND3
|
0.009x |
Annual Cash Flow Conversion Efficiency for Neurogene Inc (2011–2025)
The table below shows the annual cash flow conversion efficiency of Neurogene Inc from 2011 to 2025. View Neurogene Inc share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $264.89 Million | $-77.17 Million | -0.291x | -28.08% |
| 2024-12-31 | $310.38 Million | $-70.60 Million | -0.227x | +17.71% |
| 2023-12-31 | $186.02 Million | $-51.42 Million | -0.276x | +48.39% |
| 2022-12-31 | $98.63 Million | $-52.82 Million | -0.536x | -206.05% |
| 2021-12-31 | $-91.88 Million | $-46.40 Million | 0.505x | +492.96% |
| 2020-12-31 | $191.22 Million | $-24.57 Million | -0.129x | -18.29% |
| 2019-12-31 | $141.69 Million | $-15.39 Million | -0.109x | +75.00% |
| 2018-12-31 | $72.67 Million | $-31.58 Million | -0.435x | +3.91% |
| 2017-12-31 | $98.89 Million | $-44.72 Million | -0.452x | -116.43% |
| 2016-12-31 | $144.66 Million | $-30.23 Million | -0.209x | -11.77% |
| 2015-12-31 | $108.42 Million | $-20.27 Million | -0.187x | +62.05% |
| 2014-12-31 | $36.15 Million | $-17.81 Million | -0.493x | -218.24% |
| 2013-12-31 | $51.28 Million | $-7.94 Million | -0.155x | +98.13% |
| 2012-12-31 | $874.03K | $-7.23 Million | -8.275x | -625.11% |
| 2011-12-31 | $8.59 Million | $-9.80 Million | -1.141x | -- |
About Neurogene Inc
Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disea… Read more